Morten Albrechtsen, born 1964, has extensive experience in CNS drug development including drugs against Alzheimer’s (Enkam), depression (Boehringer Ingelheim), addiction (Nycomed, Saniona), pain control (Nycomed), insomnia (Blake Insomnia Inc. /Zleepax), and stroke (Boehringer Ingelheim, Enkam).
His experience spans from pre-clinical and clinical development to regulatory approval and to post-approval commercialization, and comprises both biological products and small molecules.